文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV与PrEP人群中伴或不伴性传播感染者的抗生素消耗:一项基于人群的观察性研究

Antibiotic consumption in HIV and PrEP populations with and without sexually transmitted infections: a population-based observational study.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

结果显示,有直肠STI记录者抗生素使用率95.3%,调整后总体抗生素暴露率为对照组的4.67倍,主要由四环素类驱动(RR-DHD 23.7)。

要点

  • 有直肠STI的HIV/PrEP人群抗生素暴露显著高于一般人群,调整率比为4.67。
  • 四环素类使用是主要驱动因素,该亚组四环素暴露率是对照组的23.7倍。
  • 无STI的HIV/PrEP人群抗生素消耗也比对照组高33%。

核心结论

  • 有直肠STI记录的HIV感染者和PrEP使用者抗生素暴露显著高于一般人群,主要由四环素类使用驱动。

研究设计与样本

  • 参与者分为三组:A组为有直肠STI记录的HIV/PrEP人群,B组为无STI的HIV/PrEP人群,C组为一般人群对照。
  • 采用倾向评分重叠权重,以每1000人日的既定日剂量(DHD)衡量抗生素消耗。

主要发现

  • A组抗生素使用率为95.3%,B组为35.4%,C组为27.3%(P < 0.001)。
  • 加权后,A组总体抗生素暴露率是一般人群的4.67倍(95% CI 4.41-4.94)。
  • A组四环素类暴露率是一般人群的23.7倍,相当于每人年约1.1个七日多西环素疗程(人群水平指标)。
  • B组抗生素消耗比对照组高33%(P = 0.004)。
  • A组四环素类使用是B组的5.6倍(P < 0.001)。

临床怎么用

  • 在性健康和HIV诊疗中应针对有直肠STI记录的HIV/PrEP人群实施靶向抗菌药物管理策略。
  • 建议进行系统性抗生素消耗监测,并对多西环素暴露后预防(doxy-PEP)进行个体化咨询。
  • 应将STI重点人群纳入国家抗菌药物耐药性监测框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial resistance is driven by antibiotic exposure. People living with HIV (PLWH) and PrEP users face high STI rates, but the magnitude of cumulative antibiotic exposure in these populations compared with the general population has not been well characterized. METHODS: This retrospective study (Madrid, 2024-2025) linked pharmacy and microbiology records of 562 325 adults. Participants were categorized into: (A) PLWH or PrEP users with documented rectal STI episodes in the context of active sexual health follow-up; (B) PrEP/PLWH without STIs; and (C) general population controls. Consumption was measured in Defined Daily Doses per 1000 persons-day (DHD) using propensity score overlap weights. RESULTS: Antibiotic use was significantly higher in Group A (95.3%) compared to Group B (35.4%) and Group C (27.3%) (P < 0.001). After weighting, individuals with documented rectal STI episodes (Group A) exhibited a markedly higher overall antibiotic exposure compared with general population controls (Group C) (adjusted rate ratio [RR]-DHD 4.67, 95% CI 4.41-4.94), driven by tetracyclines (RR-DHD 23.7), corresponding to a population rate equivalent to ∼1.1 seven-day doxycycline courses per person-year (a population-level metric, not an individual estimate). Group B consumption was 33% higher than controls (P = 0.004). Direct comparison confirmed that Group A's tetracycline use was 5.6-fold higher than Group B's (P < 0.001). CONCLUSIONS: PLWH and PrEP users with documented rectal STI episodes experience markedly higher antibiotic exposure than the general population, driven primarily by tetracycline use. This disproportionate exposure in a small, identifiable subgroup supports targeted antimicrobial stewardship strategies in sexual health and HIV care settings, including systematic consumption monitoring, individualized doxy-PEP counselling, and integration of STI-focused populations into national AMR surveillance frameworks.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Valls-Carbó A, Siguín R, Delgado-Iribarren A, et al. Antibiotic consumption in HIV and PrEP populations with and without sexually transmitted infections: a population-based observational study. J Antimicrob Chemother. 2026. PMID: 42610960. doi:10.1093/jac/dkag228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。